Ligand Pharmaceuticals to Present at Three September Conferences
Event summary
- Ligand Pharmaceuticals will participate in three investor conferences in September 2026.
- Management will host fireside chats at Wells Fargo Healthcare Conference (Sept 8) and Citi Biopharma Back to School Conference (Sept 10).
- Ligand will present at H.C. Wainwright Global Investment Conference (Sept 14).
- One-on-one investor meetings will be available during all conferences.
The big picture
Ligand's participation in these high-profile conferences underscores its position as a key player in biopharma royalty aggregation. The events provide a platform to showcase its diversified portfolio and proprietary technologies amid growing industry interest in alternative financing models. With economic interests in over 200 assets, Ligand's updates could influence broader market trends in biopharma investment strategies.
What we're watching
- Investor Sentiment
- How Ligand's presentations will impact investor perception of its royalty aggregation strategy.
- Portfolio Performance
- Whether Ligand can highlight strong performance metrics from its 200+ asset portfolio.
- Strategic Partnerships
- The pace at which Ligand expands its Captisol and NITRICIL licensing deals.